A long tradition, whose echo is still perceptible in some contemporary reflections, combines philosophy and melancholy, often indentifying melancholy as the beginning of philosophy. But rereading the ...Freud’s Mourning and Melancholia, the «circular insanity» shows two sides, depressive and maniac. Once the double nature of the «circular insanity» has been taken into consideration, it can be reiterated that melancholy is connected to philosophy not only with regard of its beginning but also to its (temporary) end, approached through Wittgenstein's reflection on the miracle and the mystical as the extinction of the philosophical question. In this perspective, the whole cycle of philosophy, from its depressive beginning to its maniacal outcome, undergoes an aesthetic consideration, in which what is more important is the how of experience rather than its what. Finally, the aesthetic point of view on the connection between melancholy and philosophy makes it possible to reconsider the very status of that research that presents itself as 'love of knowledge'.
Although Eco was deeply interested in music, his bibliography does not include a work entirely and exclusively dedicated to this theme. However, references to the problems of musical production, ...listening, interpretation and transmission are scattered in numerous essays, and are often implicitly or explicitly linked to the theoretical and compositional work of his friend and composer Luciano Berio, who in turn dialogued with the developments of Eco’s thought. This article reconstructs the intellectual relationship and friendship between Eco and Berio, originated in the fifties at the Rai studios in Milan; then it examines the passages in Eco’s work dedicated to music, from The Open Work (1962) to Kant and the Platypus (1997). Finally, the article focuses on the controversies raised by the concept of open work, conceived by Eco starting from some musical works including Berio’s Sequenza I for solo flute (1958). With respect to the freedom left to the performer in the 1958 score, Berio’s rewriting in traditional notation in the Nineties seems to undermine at its roots the idea of openness which, according to Eco, distinguishes contemporary poetics. This circumstance provoked some musicological, philological and philosophical controversies, which allowed Eco (2012) to return to reflect on the concept of open work, specifying and clarifying the aesthetic conception underlying it.
The aim of this paper is to propose an idea of musical phenomenon as event rather than as object. Music leaves the domain of objects when the sound, detached from its physical source, enters in the ...musical context (Roger Scruton). Music is a concatenation of auditory events linked with an autonomous logic; causal relations between sounds form an ideal world, different from the physical one, in which dynamic processes take place without reference to any object (Francis Wolff). The autonomy of sound from its objective source and the idea of a musical world of pure events allow us to examine the musical process as a set of auditory qualities without substratum, i.e. qualia without substance (Antonia Soulez). In this perspective, it is possible to propose a desubstanzialization of musical object that does not imply a form of skepticism about musical reality. Musical event comes rather from a complex interaction between auditory material and forces from the world outside (Pascale Criton). Considered as an event and not as an object, musical phenomenon is no more a sign for something else, even though it remains enigmatic for its double – human and “worldy” – origin.
The aim of this paper is to examine Wittgenstein’s reflections about the judgment of value. The purpose is to trace a line of continuity between the investigation about the criteria to distinguish ...propositions from nonsense, which is the main philosophical endeavour of the “first” Wittgenstein, and the subsequent philosophy of language games, presented in the Philosophical Investigations. According to the picture theory of language, as it is formulated in the Tractatus logico-philosophicus, the judgments of value do not represent facts of the world and therefore they lack of sense. In this perspective, the attempt to express experiences of “absolute value”, as Wittgenstein says in the Lecture on Ethics (1929), is condemned to nonsense, even though it testifies a typical human tendency to force the limits of language. About ten years later, in the Lessons of Aesthetics (1938) Wittgenstein analyzes the use of aesthetic adjectives in the judgments of value and he underlines the proximity of these expressions with the gesture, intended as a way to convey the feeling of the speaker in reaction to a specific experience. In the expressivity of nonsense it is possible to foresee the importance of the notion of use, a central concept in Wittgenstein’s “second” philosophy; in the analysis of aesthetic adjectives, used as gestures, it remains a link with the early investigation about the limits of language. Through the reflection on nonsense and gesture Wittgenstein develops an idea of non-communicative and expressive use of language that we can find all along his philosophical work.
Bacterial adhesion to the implant surface was the first step of peri-implant inflammation. Changes in the properties of the implant surface represent a way to reduce plaque colonization. The aim of ...this study was to evaluate the actual efficacy of titanium nitride (TiN) coated implants on antibacterial activity. Data were collected after identification of PICO. A search was performed in PubMed-Medline, Embase, Web of Knowledge, and Google Scholar using the following keywords: “Titanium nitride, dental implant coating, antibacterial activity, biofilm formation, plaque formation, modified implant surfaces, implant abutments”. The original search included 107 articles. After title and abstract screening, the number was reduced to 12. These articles were read in full text, and finally 5 articles were included in the mini-review. TiN-coated titanium appears to reduce bacterial adhesion and growth and may represent a real possibility for preventing peri-implantitis and mucositis. However, further clinical studies need to be conducted.
Cancer-associated thrombosis (CAT) is a devastating complication of cancer that can significantly impact a patient's health and life. The incidence of CAT is approximately 20%, and 1 in 5 cancer ...patients will develop CAT annually. Indeed, CAT can promote pulmonary embolism and deep vein thrombosis, leading to increased morbidity and mortality that dramatically impact survival. CAT can also provoke delay or discontinuation of anticancer treatment, which may result in a lack of treatment efficacy and high costs for patients, institutions, and society. Current guidelines advocate direct oral anticoagulants (DOACs) as the first-line anticoagulant option in CAT. Compared to low-molecular-weight-heparins (LMWHs), DOACs are advantageous in that they typically have an oral route of administration, do not require laboratory monitoring, and have a more predictable anticoagulant effect. However, in patients with thrombocytopenia, renal failure, or those receiving anticancer regimens with potential for drug-drug interactions, LMWH is still the mainstay of care. The main limitation of current anticoagulant agents is related to bleeding risk (BR), both for DOACs and LMWHs. Specifically, DOACs have been associated with high BR in gastrointestinal and genitourinary cancers. In this challenging scenario, abelacimab, an anti-factor XI agent, could represent a viable option in the management of CAT due to its "hemostasis sparing" effect. The safe profile of abelacimab could be useful in patients with active malignancy and CAT, as long-term anticoagulant therapy is often required. Two ongoing international phase III trials (Aster and Magnolia) compare abelacimab with the standard of care (i.e., apixaban in patients with CAT and dalteparin in those with CAT and high BR, respectively). Abelacimab is a new and attractive anticoagulant for the management of CAT, especially in the insidious and critical scenario of active cancer patients with venous thromboembolism and high BR. The aim of this narrative review is to discuss the updated evidence on the performance of DOACs and LMWHs in the treatment of CAT and to focus on the potential role of abelacimab in CAT and its promising associated clinical trials.Cancer-associated thrombosis (CAT) is a devastating complication of cancer that can significantly impact a patient's health and life. The incidence of CAT is approximately 20%, and 1 in 5 cancer patients will develop CAT annually. Indeed, CAT can promote pulmonary embolism and deep vein thrombosis, leading to increased morbidity and mortality that dramatically impact survival. CAT can also provoke delay or discontinuation of anticancer treatment, which may result in a lack of treatment efficacy and high costs for patients, institutions, and society. Current guidelines advocate direct oral anticoagulants (DOACs) as the first-line anticoagulant option in CAT. Compared to low-molecular-weight-heparins (LMWHs), DOACs are advantageous in that they typically have an oral route of administration, do not require laboratory monitoring, and have a more predictable anticoagulant effect. However, in patients with thrombocytopenia, renal failure, or those receiving anticancer regimens with potential for drug-drug interactions, LMWH is still the mainstay of care. The main limitation of current anticoagulant agents is related to bleeding risk (BR), both for DOACs and LMWHs. Specifically, DOACs have been associated with high BR in gastrointestinal and genitourinary cancers. In this challenging scenario, abelacimab, an anti-factor XI agent, could represent a viable option in the management of CAT due to its "hemostasis sparing" effect. The safe profile of abelacimab could be useful in patients with active malignancy and CAT, as long-term anticoagulant therapy is often required. Two ongoing international phase III trials (Aster and Magnolia) compare abelacimab with the standard of care (i.e., apixaban in patients with CAT and dalteparin in those with CAT and high BR, respectively). Abelacimab is a new and attractive anticoagulant for the management of CAT, especially in the insidious and critical scenario of active cancer patients with venous thromboembolism and high BR. The aim of this narrative review is to discuss the updated evidence on the performance of DOACs and LMWHs in the treatment of CAT and to focus on the potential role of abelacimab in CAT and its promising associated clinical trials.
The aim of this work was to systematically review and carry out a statistical metanalysis to identify the best treatment for close oroantral communications and fistulas and to avoid the risk of ...recurrence.
An electronic search was conducted on the MEDLINE database (Pubmed), Scopus, and Google scholar using the following keywords: "oro antral communication (OAC)" OR "oro antral fistula (OAF)" OR "antro-oral communication" OR "communication between maxillary sinus and oral cavity" OR "oro-sinusal communication" OR "oro-sinusal fistula" OR "sinus communication" OR "sinus fistula" OR "antral communication" AND "treatment" OR "management" OR "surgical treatment" OR "surgical interventions". This work was performed in accordance with the guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses). After article screening, 9 RCTs (randomized controlled trials), comparing two or more techniques, were included in this review.
A statistically significant difference was detected in favor of the buccal fat pad compared to the buccal advancement flap and palatal rotational flap.
With the limitations of this study, the buccal fat pad showed the best results in terms of communication closure and reducing the risk of relapse.
The gingival tissue can be collected in an easy way and represent an accessible source to isolate gingival-derived mesenchymal stem cells (GMSCs). GMSCs are a subpopulation of dental-derived ...mesenchymal stem cells that show the mesenchymal stem cells (MSCs) features, such as differentiation abilities and immunomodulatory properties. Dental-derived stem cells are also expandable in vitro with genomic stability and the possibility to maintain the stemness properties over a prolonged period of passages. Moreover, several preclinical studies have documented that the extracellular vesicles (EVs) released from GMSCs possess similar biological functions and therapeutic effects. The EVs may represent a promising tool in the cell-free regenerative therapy approach. The present review paper summarized the GMSCs, their multi-lineage differentiation capacities, immunomodulatory features, and the potential use in the treatment of several diseases in order to stimulate tissue regeneration. GMSCs should be considered a good stem cell source for potential applications in tissue engineering and regenerative dentistry.
Cardiotoxicity represents the most frequent cause with higher morbidity and mortality among long-term sequelae affecting classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) ...patients. The multidisciplinary team of Fondazione Italiana Linfomi (FIL) researchers, with the methodological guide of Istituto di Ricerche Farmacologiche "Mario Negri", conducted a systematic review of the literature (PubMed, EMBASE, Cochrane database) according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, in order to analyze the following aspects of cHL and DLBCL survivorship: (i) incidence of cardiovascular disease (CVD); (ii) risk of long-term CVD with the use of less cardiotoxic therapies (reduced-field radiotherapy and liposomal doxorubicin); and (iii) preferable cardiovascular monitoring for left ventricular (LV) dysfunction, coronary heart disease (CHD) and valvular disease (VHD). After the screening of 659 abstracts and related 113 full-text papers, 23 publications were eligible for data extraction and included in the final sample. There was an increased risk for CVD in cHL survivors of 3.6 for myocardial infarction and 4.9 for congestive heart failure (CHF) in comparison to the general population; the risk increased over the years of follow-up. In addition, DLBCL patients presented a 29% increased risk for CHF. New radiotherapy techniques suggested reduced risk of late CVD, but only dosimetric studies were available. The optimal monitoring of LV function by 2D-STE echocardiography should be structured according to individual CV risk, mainly considering as risk factors a cumulative doxorubicine dose >250 mg per square meter (m
) and mediastinal radiotherapy >30 Gy, age at treatment <25 years and age at evaluation >60 years, evaluating LV ejection fraction, global longitudinal strain, and global circumferential strain. The evaluation for asymptomatic CHD should be offered starting from the 10th year after mediastinal RT, considering ECG, stress echo, or coronary artery calcium (CAC) score. Given the suggested increased risks of cardiovascular outcomes in lymphoma survivors compared to the general population, tailored screening and prevention programs may be warranted to offset the future burden of disease.
Abstract Background Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)–positive women with early breast cancer (EBC). A careful monitoring of cardiac ...function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known. Methods and Results A total of 499 consecutive HER2-positive women (mean age 55 ± 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of >10% but ≤20% (grade 1 Tcardiotox); 15 (3%) had asymptomatic decline of LVEF of >20% or <50% (grade 2); and 16 (3%) had symptomatic heart failure (grade 3). Trastuzumab was discontinued due to cardiotoxicity in 24 patients (5%) and restarted in 13 after LVEF recovery. Forty-one percent of Tcardiotox cases occurred within the first 3 months of follow-up, most prevalently in older patients with higher creatinine levels and in patients pretreated with doxorubicin and radiotherapy. Conclusions In clinical practice ,Tcardiotox is frequent in HER2-positive women with EBC and occurs in the first 3 months of therapy. Cardiac dysfunction is mild and asymptomatic in the majority of patients. The interruption of treatment is a rare event which occurs, however, in a significantly higher percentage than reported in randomized clinical trials.
PDF
